Comparative Pharmacokinetics and Safety of 3 Different Formulations of TNX-102 2.8 mg SL Tablets and Cyclobenzaprine 5 mg Oral Tablet in Healthy Adults

Inclusion Criteria: * Healthy adults * Male or female * 18-65 years old * Non-smoker * BMI \> 18.5 and \< 30.0 * With medically acceptable form of contraception (female only) * With signed informed consent Exclusion Criteria: * Any clinically significant abnormality including ECG abnormalities or vital sign abnormalities (systolic blood pressure \< 90 or \> 140 mmHg, * Diastolic blood pressure lower \< 50 or \> 90 mmHg, or heart rate \< 50 or \> 100 BPM) * Any abnormal laboratory test (including positivity for Hep B, Hep C, HIV, and * Hemoglobin \< 128 g/L (males) or \< 115 g/L (females) and hematocrit \< 0.37 L/L (males) or \< 0.32 L/L (females)) * History of alcohol or drug abuse or dependence within 1 year and/or positive drug, cotinine, or alcohol tests * Use of any drug (within 30 days), supplement, or food (within 14 days) known to induce or inhibit hepatic drug metabolism prior to study medication * Positive pregnancy test, breastfeeding or lactating * Use of medication other than hormonal contraceptives or topical products, including OTC, natural health products, MAO inhibitors * Participation in an investigational study within 30 days prior to dosing * Donation of plasma (within 7 days), or donation or loss of blood of 50-499 mL (within 30 days), or of \> 499 mL (within 56 days) prior to dosing.